PER

3.57%

8.7¢ percheron therapeutics limited

Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-151

First 151 Last

Share
Profile

Follow
RYNZN

3,132 Posts.

507

10/06/21

15:41

Post #: 53772403
Share

Originally posted by Vinceanna: ↑

Alzheimer’s Decision Sends Positive Message to Aussie Biotechs

This is from Dr.G. Price Point of view:

A prominent US physician and consultant to Antisense Therapeutics (ASX:ANP), Dr Gil Price notes the FDA’s approval was based on complex data set. That being the case, Biogen will conduct a controlled trial for the verification of Aduhelm clinical benefit in patients with AD.

“But if Antisense Therapeutics produces similar data, we would expect a similar decision from FDA,” says Price, a former director of the Nasdaq-listed Duchenne muscular dystrophy (DMD) drug developer Sarepta Therapeutics.

Antisense is is planning to pursue FDA “fast track” designation for its DMD drug candidate ATL1102. DMD is an incurable muscle wasting disorder that affects one in every 3600 to 6000 male children.

The company is currently discussing the construct of a proposed phase 2b/3 trial with the FDA.

However Price says the FDA’s decision does not constitute a lowering of standards. “The FDA reviewed data in a very difficult therapeutic area, and made a reasonable decision that offers patients hope,” he says.

“Keep in mind that FDA has been working with Biogen over the past 10 years as a partner, more than an overseer.“

Antisense Therapeutics appreciates the culture at FDA for the development of drugs that treat rare diseases and hopes to build a similar relationship as we continue to move forward.”

Expand

“But if Antisense Therapeutics produces similar data, we would expect a similar decision from FDA,” says Price

nice if he is speaking about Alzheimer’s, as one of our new indications, price will go gangbusters.

ANP Price at posting: 22.5¢ Sentiment: Buy Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

HLX

Helix investor makes partial takeover bid, proposing board changes

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

There are more pages in this discussion • 41 more messages in this thread...

First 151 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.7¢		Change 0.003(3.57%)		Mkt cap ! $78.43M

Open	High	Low	Value	Volume
8.4¢	8.7¢	8.4¢	$72.99K	855.8K

Buyers (Bids)

No.	Vol.	Price($)
2	452608	8.4¢

Sellers (Offers)

Price($)	Vol.	No.
8.7¢	398595	1

View Market Depth

No.	Vol.	Price($)
2	452608	0.084
3	212500	0.083
2	106250	0.080
2	125578	0.079
1	12462	0.078

Price($)	Vol.	No.
0.087	398595	1
0.088	400000	1
0.089	135000	2
0.090	794374	5
0.092	50000	1

Last trade - 16.10pm 30/08/2024 (20 minute delay)

PER (ASX) Chart

Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-151

The Calmer Co’s Anthony Noble reflects on record breaking FY24

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Lendlease sells off US east coast construction operations in latest global divestment push

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Helix investor makes partial takeover bid, proposing board changes

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-151

Top Stories

The Calmer Co’s Anthony Noble reflects on record breaking FY24

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Lendlease sells off US east coast construction operations in latest global divestment push

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Helix investor makes partial takeover bid, proposing board changes

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News